Literature DB >> 10675577

Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis.

K H Rand1, H Houck, N D Denslow, K M Heilman.   

Abstract

Oligoclonal bands (OCBs) are frequently observed in the cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS), but the target antigens of these antibodies remain unknown. We used antigen specific immunoblotting to determine whether Epstein Barr virus nuclear antigen-1 (EBNA-1) was a target of the OCBs in the CSF of patients with MS. Antibody indices (AIs) were measured by ELISA and calculated by the formula of Reiber and Lange which includes correction factors for both breakdown of the blood brain barrier and intrathecal polyclonal IgG synthesis. A distinctive oligoclonal antigen specific banding pattern for EBNA-1 was observed in 5/15 MS patients, but 0/12 controls (P=0.037, Fisher's Exact Probability). AIs in this EBNA-l positive subgroup were extremely high, comparable with levels observed in viral CNS infections. In one patient with EBNA-1 specific OCBs, EBNA-1 and a peptide 'equivalent', p62, were able to absorb a component of the total IgG. Our results suggest that in a subset of MS patients, EBNA-1 may be a major target of selected OCBs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10675577     DOI: 10.1016/s0022-510x(99)00298-1

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  24 in total

Review 1.  Development of anti-CD20 therapy for multiple sclerosis.

Authors:  Beatrix Bartok; Gregg J Silverman
Journal:  Exp Cell Res       Date:  2011-04-12       Impact factor: 3.905

Review 2.  99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Epstein-Barr virus and multiple sclerosis: epidemiological evidence.

Authors:  A Ascherio; K L Munger
Journal:  Clin Exp Immunol       Date:  2010-04       Impact factor: 4.330

Review 3.  Epstein-barr virus infection and multiple sclerosis: a review.

Authors:  Alberto Ascherio; Kassandra L Munger
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-06       Impact factor: 4.147

4.  Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome.

Authors:  Diana Ferraro; Veronica Galli; Anna Maria Simone; Roberta Bedin; Francesca Vitetta; Elisa Merelli; Paolo Frigio Nichelli; Patrizia Sola
Journal:  J Neurovirol       Date:  2016-11-22       Impact factor: 2.643

Review 5.  Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.

Authors:  Klemens Ruprecht; Brigitte Wildemann; Sven Jarius
Journal:  J Neurol       Date:  2017-11-02       Impact factor: 4.849

6.  Intrathecal antibody production against Epstein-Barr and other neurotropic viruses in pediatric and adult onset multiple sclerosis.

Authors:  Daniela Pohl; Kevin Rostasy; Christian Jacobi; Peter Lange; Roland Nau; Bernd Krone; Folker Hanefeld
Journal:  J Neurol       Date:  2009-08-28       Impact factor: 4.849

7.  Human endogenous retrovirus-K18 Env as a risk factor in multiple sclerosis.

Authors:  A K Tai; E J O'Reilly; K A Alroy; K C Simon; K L Munger; B T Huber; A Ascherio
Journal:  Mult Scler       Date:  2008-08-13       Impact factor: 6.312

8.  Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.

Authors:  R A Farrell; D Antony; G R Wall; D A Clark; L Fisniku; J Swanton; Z Khaleeli; K Schmierer; D H Miller; G Giovannoni
Journal:  Neurology       Date:  2009-05-20       Impact factor: 9.910

9.  Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.

Authors:  Simon N Willis; Christine Stadelmann; Scott J Rodig; Tyler Caron; Stefan Gattenloehner; Scott S Mallozzi; Jill E Roughan; Stefany E Almendinger; Megan M Blewett; Wolfgang Brück; David A Hafler; Kevin C O'Connor
Journal:  Brain       Date:  2009-12       Impact factor: 13.501

10.  A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk.

Authors:  Cecilia Ahlgren; Kjell Torén; Anders Odén; Oluf Andersen
Journal:  Eur J Epidemiol       Date:  2009-07-26       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.